VOR

Vor Biopharma Inc

VOR, USA

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

https://www.vorbio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VOR
stock
VOR

Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors ts2.tech

Read more →
VOR
stock
VOR

Vor Biopharma Approves Stock Option Repricing Plan TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$50.3333

Analyst Picks

Strong Buy

0

Buy

0

Hold

5

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.04

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

36.52 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-461.13 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 48.15% of the total shares of Vor Biopharma Inc

1.

RA Capital Management, LLC

(31.2954%)

since

2025/06/30

2.

5AM Venture Management, LLC

(5.0218%)

since

2025/06/30

3.

FMR Inc

(1.6519%)

since

2025/06/30

4.

Vanguard Group Inc

(1.5121%)

since

2025/06/30

5.

UBS Group AG

(1.209%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(1.0702%)

since

2025/07/31

7.

Johnson & Johnson

(0.8483%)

since

2025/06/30

8.

Fidelity VIP Growth Initial

(0.4881%)

since

2025/07/31

9.

Jane Street Group LLC

(0.4149%)

since

2025/06/30

10.

Sarissa Capital Management LP

(0.401%)

since

2025/06/30

11.

HRT FINANCIAL LLC

(0.3746%)

since

2025/06/30

12.

Fidelity Advisor Equity Growth I

(0.3743%)

since

2025/07/31

13.

Renaissance Technologies Corp

(0.3695%)

since

2025/06/30

14.

Geode Capital Management, LLC

(0.3438%)

since

2025/06/30

15.

Scientech Research LLC

(0.3188%)

since

2025/06/30

16.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3166%)

since

2025/07/31

17.

BlackRock Inc

(0.2958%)

since

2025/06/30

18.

Virtu Financial LLC

(0.2178%)

since

2025/06/30

19.

Fidelity Growth Discovery

(0.1932%)

since

2025/07/31

20.

Fidelity Extended Market Index

(0.1661%)

since

2025/07/31

21.

Goldman Sachs Group Inc

(0.1427%)

since

2025/06/30

22.

Two Sigma Investments LLC

(0.1339%)

since

2025/06/30

23.

Galileo - Biotech Innovation Fund S USD

(0.1281%)

since

2025/02/28

24.

Goldman Sachs Absolute Ret Trckr Instl

(0.1175%)

since

2025/06/30

25.

State Street Corp

(0.0915%)

since

2025/06/30

26.

TWO SIGMA SECURITIES, LLC

(0.0745%)

since

2025/06/30

28.

Citigroup Inc

(0.0691%)

since

2025/06/30

29.

Fidelity Total Market Index

(0.0607%)

since

2025/07/31

30.

Fidelity Nasdaq Composite Index

(0.0539%)

since

2025/07/31

31.

Pacific Select Large-Cap Growth I

(0.0506%)

since

2025/08/31

32.

Extended Equity Market Fund K

(0.0442%)

since

2025/06/30

33.

Fidelity Series Total Market Index

(0.0411%)

since

2025/07/31

34.

Fidelity Advisor Series Equity Gr

(0.0346%)

since

2025/07/31

35.

Spartan Extended Market Index Pool F

(0.0336%)

since

2025/07/31

36.

NT Ext Equity Mkt Idx Fd - L

(0.0284%)

since

2025/06/30

37.

Northern Trust Extended Eq Market Idx

(0.0284%)

since

2025/06/30

38.

NT Ext Equity Mkt Idx Fd - NL

(0.0237%)

since

2025/06/30

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0215%)

since

2024/12/31

40.

Spartan Total Market Index Pool G

(0.0205%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-121.63

EPS Estimate

-0.104

EPS Difference

-121.526

Surprise Percent

-116851.9231%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.